Clinical-stage biopharmaceutical company developing targeted protein degradation medicines
Clinical-stage biopharmaceutical company developing targeted protein degradation medicines. Its DEL-AI drug discovery engine supports a pipeline of degrader therapies and degrader antibody conjugates for oncology, immunology, and neurology.